Compare DexCom, Inc. (DXCM) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs VanEck Vietnam ETF — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while VanEck Vietnam ETF trades at $16.72 (market cap $469.76M). The key difference: DexCom, Inc. is far larger — about 67.8× VanEck Vietnam ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and VanEck Vietnam ETF for 51 Days on average.
| DXCM | VNM | |
|---|---|---|
Market Cap | $31.86B | $469.76M |
Volume | 3,607,070 | 375,157 |
Sector | Health | Sector/Thematic |
52-Week High | $92.34 | $19.80 |
52-Week Low | $54.84 | $16.34 |
Typical Hold Time | 62 Days | 51 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
VNM trades at $16.72, down 0.89% today, with a bearish technical signal from moving averages but bullish momentum from oscillators. The stock faces sector concentration risks in real estate and financials while benefiting from Vietnam's potential US trade deal progress. Key support and resistance cluster around $17, with RSI levels indicating potential oversold conditions.
The outlook remains cautious due to sector headwinds and interest rate sensitivity, though fair valuation and macroeconomic growth prospects offer long-term potential. Near-term performance depends on trade developments and sector stability, with institutional sentiment mixed on timing and risk exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
